Medicinova (MNOV) 3.62 $MNOV
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:45AM CST
CYTK: 7.78 (+1.29), MNOV: 3.62 (-0.56), MX: 7.52 (-7.50), SIEB: 1.71 (-0.24), QKLS: 2.10 (-0.24), YUMA: 1.88 (+0.67), CYBR: 52.52 (+6.83), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), CECO: 5.34 (-0.92), GENE: 8.04 (+1.90), SGNL: 3.91 (+2.15), IMI: 1.70 (-0.20), RCKY: 18.43 (+4.33), WAC: 20.29 (+2.57), FNJN: 2.77 (-0.36), ZNGA: 2.24 (-0.42), PRAN: 1.09 (-0.55)
MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF
GlobeNewswire - Tue Feb 10, 8:07AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that FDA (U.S. Food and Drug Administration) has approved the protocol for a clinical trial of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis). Importantly, due to safety data from previous clinical studies of MN-001, FDA has agreed that MediciNova may proceed with a Phase 2 study as the first clinical trial of MN-001 in IPF. The IPF protocol was filed under MediciNova's open IND (Investigational New Drug Application) in FDA's Division of Pulmonary, Allergy, and Rheumatology Products (DPARP). FDA has granted orphan-drug designation to MN-001 for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if MN-001 is approved for IPF.
MNOV: 3.62 (-0.56)
MediciNova awarded Notice of Allowance for MN-001 and MN-002 for NASH from US Patent and Trademark Office
M2 - Wed Feb 04, 5:23AM CST
Biopharmaceutical company
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:45AM CST
CYTK: 7.78 (+1.29), MNOV: 3.62 (-0.56), MX: 7.52 (-7.50), SIEB: 1.71 (-0.24), QKLS: 2.10 (-0.24), YUMA: 1.88 (+0.67), CYBR: 52.52 (+6.83), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), CECO: 5.34 (-0.92), GENE: 8.04 (+1.90), SGNL: 3.91 (+2.15), IMI: 1.70 (-0.20), RCKY: 18.43 (+4.33), WAC: 20.29 (+2.57), FNJN: 2.77 (-0.36), ZNGA: 2.24 (-0.42), PRAN: 1.09 (-0.55)
MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF
GlobeNewswire - Tue Feb 10, 8:07AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that FDA (U.S. Food and Drug Administration) has approved the protocol for a clinical trial of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis). Importantly, due to safety data from previous clinical studies of MN-001, FDA has agreed that MediciNova may proceed with a Phase 2 study as the first clinical trial of MN-001 in IPF. The IPF protocol was filed under MediciNova's open IND (Investigational New Drug Application) in FDA's Division of Pulmonary, Allergy, and Rheumatology Products (DPARP). FDA has granted orphan-drug designation to MN-001 for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if MN-001 is approved for IPF.
MNOV: 3.62 (-0.56)
MediciNova awarded Notice of Allowance for MN-001 and MN-002 for NASH from US Patent and Trademark Office
M2 - Wed Feb 04, 5:23AM CST
Biopharmaceutical company
